By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Otsuka Pharmaceutical Co., Ltd. 

2-9 Kanda Tsukasa-cho
Tokyo    101-8535  Japan
Phone: 03-3292-0021 Fax:



Company News
Otsuka Pharma Release: ABILIFY MAINTENA (Aripiprazole) For Extended-Release Injectable Suspension Approved By U.S. FDA For Maintenance Monotherapy Treatment Of Bipolar I Disorder 7/31/2017 7:31:34 AM
Otsuka Pharma Announces The Acquisition Of Rapidly Growing Plant-Based Food Innovator Daiya 7/28/2017 6:55:09 AM
Otsuka Pharma And Proteus Digital Health Resubmit Application To FDA For First Digital Medicine 5/23/2017 9:14:56 AM
Otsuka Pharma Announces Results Of Phase III Data On Tolvaptan 5/22/2017 7:28:47 AM
Otsuka Pharma And Teva (TEVA) Sign Licensing Agreement For Japan On Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125) 5/15/2017 9:06:10 AM
Otsuka Pharma Release: Launch Of Alzheimer’s Journey Coordinator Certificate Program 5/10/2017 9:12:14 AM
Mixed Data For Alzheimer’s-Type Dementia Drug Leave Lundbeck (LUN.CO), Otsuka Pharma Investors Unsettled 5/2/2017 6:52:45 AM
Otsuka Pharma And Lundbeck (LUN.CO) Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia 5/2/2017 6:52:20 AM
Why Akebia (AKBA), Even With Otsuka Pharma's Big Deal, May Need To Be Acquired 4/27/2017 7:07:32 AM
Otsuka Pharma Believes in Akebia (AKBA), Commits Another $865 Million to Expand Anemia Deal 4/26/2017 5:38:54 AM